Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
暂无分享,去创建一个
R. Advani | J. Connors | T. Illidge | N. Bartlett | P. Brice | R. Ramchandren | M. Fanale | B. Pro | J. Rosenblatt | J. Matous | E. Sievers | A. Shustov | D. Kennedy | Yin Yang